Tempest Therapeutics, INC 8-K filings

Tempest Therapeutics reported Q2 2026 financial results, highlighting a new development collaboration for TPST-4003, positive interim data for TPST-2003, and strategic board appointments.

Tempest Therapeutics has entered into a $50 million purchase agreement with Lincoln Park Capital Fund, LLC, providing a flexible equity financing option.

Tempest Therapeutics has adjourned its special meeting of stockholders to allow for additional voting time on a proposed amendment to its Certificate of Incorporation.

Tempest Therapeutics and Hebei Senlang Biotechnology have entered into a collaboration agreement to develop Tempest's TPST-4003 CAR-T candidate, initiating with an investigator-initiated trial in China.

Tempest Therapeutics has appointed two new independent directors and a new Principal Financial Officer to address board vacancies and leadership transitions.

Tempest Therapeutics announced the resignation of board member Ms. Simantov effective May 23, 2026.

Tempest Therapeutics has received notice of non-compliance with Nasdaq equity and board independence requirements.

Three directors have resigned from the Tempest Therapeutics Board of Directors effective May 22, 2026.

Tempest Therapeutics announced first quarter 2026 financial results, highlighting positive interim data for its TPST-2003 CAR-T therapy in multiple myeloma and appointing a new Head of Business Development.

Tempest Therapeutics announced strong clinical data for its lead CAR-T therapy candidate, TPST-2003, showing a 100% complete response rate in certain patient groups.

Tempest Therapeutics reported a narrower 2025 loss with $7.7M cash, unveiled 100% CR in early rrMM CAR-T data, closed CAR-T asset acquisition, and outlined 2026 registrational study plans.

Tempest Therapeutics, Inc. announced a private placement of common stock and warrants, raising $2.0 million initially with potential for an additional $4.0 million.

Tempest Therapeutics announced compelling interim results from its REDEEM-1 trial for TPST-2003, a dual-targeting CAR-T therapy, showing a 100% complete response rate in evaluable patients with relapsed/refractory multiple myeloma.

Tempest Therapeutics highlights positive clinical data for its oncology pipeline, including promising CAR-T results and a pivotal Phase 3 path for its HCC therapy.

Tempest Therapeutics completed the acquisition of four CAR T-cell therapy assets, issued new warrants, and announced significant changes to its Board and executive leadership, including a new CEO.

Tempest Therapeutics' stockholders approved the extension of its rights plan, an increase in its equity incentive plan, and the issuance of shares for an asset purchase at the 2025 Annual Meeting.

Tempest Therapeutics received a Nasdaq delisting notice for failing to hold its annual meeting, but has scheduled the meeting for January 27, 2026, to regain compliance.

Tempest Therapeutics announced a registered direct offering and concurrent private placement, raising $4.25 million upfront with potential for an additional $4.1 million.

Tempest Therapeutics announced the acquisition of four CAR T-cell therapy programs from Erigen LLC and Factor Bioscience Inc., alongside significant leadership changes and a planned capital raise.

Tempest Therapeutics announced its third quarter 2025 financial results, reporting a significant decrease in cash and continued net losses while actively exploring strategic alternatives.

Tempest Therapeutics announced its second quarter 2025 financial results, highlighting clinical advancements for its cancer therapies and ongoing strategic alternatives exploration.

Tempest Therapeutics, Inc. announced a registered direct offering of common stock and prefunded warrants, raising approximately $4.1 million in net proceeds to fund operations into the second quarter of 2026.

Tempest Therapeutics, Inc. announced the suspension and termination of its prospectus supplement related to its at-the-market (ATM) equity offering program with Jefferies LLC, effective June 11, 2025.

Tempest Therapeutics, Inc. announced that its CEO, CMO, and CFO have transitioned to consulting agreements as the company explores a full range of strategic alternatives to extend its capital resources.

Tempest Therapeutics announced its Q1 2025 financial results, highlighting progress with amezalpat and TPST-1495, while also revealing strategic alternatives and a workforce reduction.

Tempest Therapeutics has received notification from Nasdaq confirming its compliance with the minimum bid price requirement of $1.00 per share.

Tempest Therapeutics plans to reduce its workforce by 21 employees to extend capital resources as it explores strategic alternatives.

Tempest Therapeutics announces it is exploring strategic alternatives, including potential mergers or acquisitions, due to unfavorable capital market conditions despite positive clinical data.

Tempest Therapeutics enacts a 1-for-13 reverse stock split to increase its stock price and maintain Nasdaq compliance.

Tempest Therapeutics announced its year-end 2024 financial results, highlighting progress with Amezalpat and TPST-1495, along with key regulatory designations and a collaboration with Roche.